#multistem

Overselling stem cells for COVID-19: WSJ article & UMN PR

Many are  jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype.

I’ve called this collective trend of promotion of scads of trials of cell therapies for COVID…

About that Athersys stem cell stroke clinic trial PR…

There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year.

This sounds encouraging and the stock has spiked up as a result.

However, there are some naysayers including long-time stem cell biotech critic Adam…

Stem Cell Treatments for Stroke: A Tale of Two Trials

Two different clinical trials that examined the efficacy of stem cell treatments after a stroke have yielded very different results.

“Stroke” refers to a serious medical condition that occurs when the blood supply to the brain is disrupted by blockage of or injury to blood vessels that supply the brain with blood. Strokes cause a loss of, or reduction in, brain function. There are two main types…